<DOC>
	<DOCNO>NCT01040871</DOCNO>
	<brief_summary>This randomize , open-label , active-control , parallel-group , multicenter , multinational Phase 2 Study efficacy safety VELCADE , Rituximab , Cyclophosphamide , Doxorubicin , Prednisone ( VR-CAP ) Rituximab , Cyclophosphamide , Doxorubicin , Vincristine , Prednisone ( R-CHOP ) Patients With Newly Diagnosed Non-Germinal Center B-Cell ( non-GCB ) Subtype Diffuse Large B-Cell Lymphoma ( DLBCL )</brief_summary>
	<brief_title>Study Combination VELCADE , Rituximab , Cyclophosphamide , Doxorubicin , Prednisone Rituximab , Cyclophosphamide , Doxorubicin , Vincristine , Prednisone Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Male female patient 18 year old . Newly Diagnosed nonGCB subtype DLBCL ( Stage II , III IV ) . At least 1 measurable site disease . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Female subject must postmenopausal ( least 6 month ) , surgically sterile , abstinent , , sexually active , practice effective method birth control entry throughout study ; negative pregnancy test screening . Male subject must agree use double barrier method birth control Prior treatment VELCADE . Prior extend radiotherapy chemotherapy lymphoma More 150 mg/m2 prior doxorubicin Major surgery within 3 week study . Peripheral neuropathy neuralgia Grade 2 worse . Active CNS lymphoma Diagnosed treated malignancy NHL , exception Pregnant breast feed Active systemic infection Documented suspect human immunodeficiency virus ( HIV ) /AIDS Uncontrolled severe cardiovascular disease Known allergy , hypersensitivity intolerance study drug Serious medical condition could interfere study Concurrent treatment another investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>